

**FIG. 1**

# BINDING




FIG. 2A

# BINDING INHIBITION






FIG. 2B


09776781.020601




*FIG. 2C*




*FIG. 2D*




*FIG. 3A*



*FIG. 3B*



*FIG. 3C*



(125-PRO) IL-2 (mM)

(125-PRO) IL-2 (mM)

IL-9 (u/ml)

FIG. 4A

FIG. 4B

FIG. 4C




FIG. 4D




FIG. 4E







FIG. 4F



**FIG. 5A**




**FIG. 5B**



**FIG. 5C**

INTERLEUKINE-2 RECEPTOR



**FIG. 6A**



IL-2 AND IP 130 SEQUENCE ( $\alpha$ -HELICES ARE BOXED)




FIG. 6B

[illegible]

IP130 ( $\mu\text{M}$ )	[ $^3\text{H}$ ] TdR INCORPORATION ( $\times 10^{-3}$ )
0	~0.2
~2	~0.2
~5	~0.2
~10	~0.2
50	~7.5
100	~5.5




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D




FIG. 9A

FIG. 9B

FIG. 9C





FIG. 9D

FIG. 9E


1	10	20	30		% HELIX (CIRCULAR DICHROISM)	MAIN MOLECULAR SPECIES	ACTIVITY
APTSSSTKTQLQLEHLLDLQMILGINN							
1			30		50% (150 @ 30 $\mu$ M) 35% (4 $\mu$ M)	TETRAMER (4M-8M, K <sub>d</sub> =30-100 $\mu$ M) /OCTAMER	+++
	10		30		22% (150 @ 30 $\mu$ M)	DIMER (1M-2M, K <sub>d</sub> =0.2 $\mu$ M) /TETRAMER (2M-4M, K <sub>d</sub> =100 $\mu$ M)	++
1					<2%		-
1	10				0%	DIMER (1M-2M, K <sub>d</sub> =50 $\mu$ M) (2M-4M, K <sub>d</sub> =1.4mM)	-
	5	15			0%	DIMER (1M-2M, K <sub>d</sub> =113 $\mu$ M)	-
	10	20			0%	MONOMER	ND
		20	20		<5%	MONOMER	+

FIG. 10



IP130

*FIG. 11A*



IP130

*FIG. 11B*







FIG. 12A




F I G . 1 2 B

NO STIMULATION  
IL - 2  
IP 130  
IL - 2 + IP 130

FIG. 13



ACTIVATED STATs



IL-2 RECEPTOR AND ITS MAJOR SIGNAL TRANSDUCTION PATHWAY MODEL OF TRANSDUCTION PATHWAY INDUCED BY IP130

FIG. 14

NK CELLS (CD56<sup>+</sup>) ENTERING IN S+G2/M PHASES AFTER IP130 STIMULATION  
(SYNERGY WITH IL-2)

TREATMENT			J31	J32	J33
IL-2 50 nM			14	12	14
	IP130	60 $\mu$ M	0	17	$\leq 5$
	IP130	120 $\mu$ M	0	14	$< 5$
IL-2 50 nM +	IP130	60 $\mu$ M	26	21	7
IL-2 50 nM +	IP130	120 $\mu$ M	28	28	28

**FIG. 15**

0976781.020601




FIG. 16B

FIG. 16A




FIG. 16D

FIG. 16C




FIG. 16F




FIG. 16E






FIGURE 17




FIGURE 18

09776781 020604




FIGURE 19